Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · IEX Real-Time Price · USD
3.470
+0.080 (2.36%)
At close: Mar 27, 2024, 4:00 PM
3.450
-0.020 (-0.58%)
Pre-market: Mar 28, 2024, 7:15 AM EDT

Trevi Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017
Cash & Equivalents
32.412.5936.834557.317.222.02
Short-Term Investments
50.57107.9200000
Cash & Cash Equivalents
82.97120.5136.834557.317.222.02
Cash Growth
-31.15%227.21%-18.16%-21.48%695.79%-67.29%-
Other Current Assets
4.582.111.131.272.241.620.14
Total Current Assets
87.55122.6237.9646.2759.558.8222.16
Property, Plant & Equipment
1.560.190.180.330.430.150.01
Other Long-Term Assets
0.30.210.330.530.021.550.05
Total Long-Term Assets
1.860.40.520.860.451.70.07
Total Assets
89.4123.0238.4847.136010.5322.23
Accounts Payable
1.812.862.852.021.60.60.54
Current Debt
0.317.036.070.110.105.29
Other Current Liabilities
3.713.523.813.433.52.071.3
Total Current Liabilities
5.8213.412.725.565.22.687.13
Long-Term Debt
1.032.158.6814.290.260.050
Other Long-Term Liabilities
00000117.399.53
Total Long-Term Liabilities
1.032.168.6814.290.26117.3499.53
Total Liabilities
6.8615.5621.419.855.46120.02106.66
Total Debt
1.349.1814.7414.410.360.055.29
Debt Growth
-85.42%-37.75%2.33%3946.91%673.91%-99.13%-
Retained Earnings
-239.13-210.07-180.92-146.98-114.22-109.5-84.43
Comprehensive Income
-0.03-0.1200000
Shareholders' Equity
82.55107.4617.0827.2854.55-109.49-84.43
Net Cash / Debt
81.63111.3322.0930.5956.967.1616.74
Net Cash / Debt Growth
-26.68%404.06%-27.81%-46.29%695.93%-57.24%-
Net Cash Per Share
0.821.720.971.694.8516.3539.78
Working Capital
81.72109.2225.2340.7154.356.1515.04
Book Value Per Share
0.831.670.751.514.65-250.21-200.68
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).